Buy Pfizer Stock Info

The market currently views Pfizer through the lens of its "COVID hangover" and an impending "patent cliff." However, for long-term investors, the current valuation may represent an attractive entry point based on three primary pillars:

As of April 2026, the case for buying Pfizer (PFE) stock centers on its status as a "deep value" play with a high dividend yield, contrasted against significant mid-term revenue headwinds. Following its late-2025 financial guidance, which projected flat to slightly declining revenue for 2026, the stock has traded at a significant discount to its historical norms and the broader S&P 500. buy pfizer stock

: Pfizer anticipates a $1.5 billion revenue headwind in 2026 due to patent expirations, with these losses projected to accelerate to over $6 billion annually by 2028 . The market currently views Pfizer through the lens

: Official 2026 guidance forecasts revenue between $59.5 billion and $62.5 billion , a slight decline from 2025 levels. This "soft" outlook has led many major brokerages, such as Bank of America and Bernstein , to maintain "Neutral" or "Hold" ratings. : Official 2026 guidance forecasts revenue between $59

Potential buyers must weigh the value proposition against structural challenges that may limit near-term price appreciation:

: The success of Pfizer's $43 billion Seagen acquisition and its internal obesity assets is critical. Any setbacks in late-stage trials or slower-than-expected integration of new assets could further delay the "growth inflection" point, currently estimated for 2028 or 2029 . Summary of Analyst Outlook Metric / Sentiment Consensus Rating Moderate Buy / Hold Average Price Target ~$28.48 to $29.42 Dividend Yield 6.37% – 6.51% 2026 EPS Guidance $2.80 – $3.00